Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
The French drugmaker is expanding its neurology activities with the $470m deal.
The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.
The German biotech has been forced into insolvency and NASDAQ suspension.
The company hopes the drug will become the standard of care rescue treatment in asthma.
The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.
Vyepti revenues rise by nearly 70% in the first quarter.